Full-Length Transcriptome Sequencing: An Insight Into the Dog Model of Heart Failure

Xiaoyan Liang, Zechen Bai, Feifei Wang, Yafan Han, Huaxin Sun, Jiasuoer Xiaokereti, Ling Zhang, Xianhui Zhou, Yanmei Lu, Baopeng TangFrontiers in Cardiovascular Medicine 2021 · DOI

TL;DR

This study leverages full-length transcriptome sequencing on a canine model of heart failure (HF) to provide a comprehensive view of the transcriptional landscape. By identifying differentially expressed transcripts and alternative splicing events, the research sheds light on the immune response and sarcomeric gene regulation in HF, offering valuable insights for therapeutic development.

What Problem Does This Paper Address?

Heart failure (HF) is a growing global health crisis with significant morbidity and mortality. Understanding the complex molecular mechanisms underlying HF is crucial for developing effective treatments. While previous studies have used transcriptomics to investigate HF, limitations in short-read sequencing technologies often missed a complete picture of alternative splicing (AS) events and novel transcripts. This paper aims to address this gap by employing full-length transcriptome sequencing (FLT-Seq) on a large animal model (dogs) to capture a more comprehensive and accurate view of the HF transcriptome, including AS isoforms and non-coding RNAs.

Methods

The study utilized a rapid ventricular pacing (RVP) model in beagles to induce heart failure. Full-length transcriptome sequencing was performed on myocardial tissues using the Oxford Nanopore Technologies (ONT) platform. This approach allows for the generation of long reads, which are essential for accurately identifying and quantifying full-length transcripts and alternative splicing events.

Key analytical methods included:

  • Differential Expression Analysis (DESeq2): To identify transcripts with significantly different expression levels between HF and control groups.
  • Functional Annotation (GO and KEGG): To understand the biological pathways and functions associated with differentially expressed transcripts.
  • Alternative Splicing (AS) Analysis (AStalavista): To identify and characterize various types of AS events.
  • Transcription Factor (TF) and Long Non-coding RNA (lncRNA) Prediction: Using specialized databases and computational tools.
  • Flow Cytometry: To quantify the proportions of different T-helper cell subsets (Th1, Th2, Th17).
  • Quantitative Real-Time PCR (qRT-PCR): To validate the expression levels of selected genes.

Datasets

The study generated and analyzed transcriptomic data from myocardial tissues of three control dogs and three HF dogs. The raw sequencing data has been deposited in the SRA database under accession number PRJNA731299. No external datasets were used for training or evaluation in this specific study.

Key Insights and Ideas

  • FLT-Seq is powerful for HF research: The study demonstrates the utility of long-read sequencing in capturing a more complete transcriptomic profile of HF, including previously overlooked AS events and novel transcripts.
  • Immune dysregulation is central to HF: The findings strongly implicate immune responses, particularly the differentiation of Th1 and Th17 cells, as key players in the development of HF. This suggests that targeting immune pathways could be a promising therapeutic strategy.
  • Sarcomeric gene splicing is altered in HF: The identification of variable splicing events in crucial sarcomeric genes highlights a potential mechanism by which cardiac contractility and function are compromised in HF.
  • TFs and lncRNAs are involved in HF pathogenesis: The study identified a significant number of differentially expressed transcription factors and lncRNAs associated with HF, suggesting their roles in regulating gene expression and cellular processes relevant to the disease.

Key Results

  • HF Model Validation: The RVP model successfully induced HF, characterized by reduced ejection fraction (EF), increased B-type natriuretic peptide (BNP) levels, and histological evidence of myocardial fibrosis.
  • Transcriptome Landscape: 67,458 non-redundant transcripts and 23,734 annotated genes were identified.
  • Differentially Expressed Transcripts (DETs): A total of 785 DETs were identified between HF and control groups, with 338 upregulated and 447 downregulated.
  • Immune Cell Profiling: Flow cytometry revealed an increased proportion of Th1 and Th17 cells and a decreased proportion of Th2 cells in HF patients compared to controls.
  • Immune Pathway Enrichment: DETs were significantly enriched in pathways related to Th1, Th2, and Th17 cell differentiation.
  • Alternative Splicing: 3,746 AS events were identified, with exon skipping (ES) being the most prevalent. Notably, five sarcomere genes (TTN, TNNI2, TNNI3, MYBPC3, and FLNC) exhibited variable splicing.
  • Transcription Factors and lncRNAs: 4,892 transcription factors and 406 lncRNAs were identified, with differential expression observed in both categories.

Limitations and Future Work

The authors acknowledge several limitations:

  • Sequencing Capacity: The nanopore sequencing capacity might not have been sufficient to detect all genes, especially those with low expression levels.
  • Transcript Variant Characterization: While AS events were identified, in-depth characterization of these transcript variants and their functional impact requires further investigation.

Future work should focus on:

  • Detailed functional studies of TFs and lncRNAs: To elucidate their precise roles in HF pathogenesis.
  • In-depth characterization of AS events: To understand how aberrant splicing contributes to HF and to explore their potential as diagnostic or prognostic markers.
  • Further validation of findings: Using larger cohorts and different experimental models.

Summary updated

Abstract

Heart failure (HF) leads to a progressive increase in morbidity and mortality rates. This study aimed to explore the transcriptional landscape during HF and identify differentially expressed transcripts (DETs) and alternative splicing events associated with HF. We generated a dog model of HF (<i>n</i> = 3) using right ventricular pacemaker implantation. We performed full-length transcriptome sequencing (based on nanopore platform) on the myocardial tissues and analyzed the transcripts using differential expression analysis and functional annotation methods [Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) analyses]. Additionally, we estimated the expression of the selected genes by quantitative real-time PCR (qRT-PCR) and detected the proportion of immune cells using flow cytometry. We found that increased B-type natriuretic peptide reduced ejection fraction, and apparent clinical signs were observed in the dog model of HF. We identified 67,458 transcripts using full-length transcriptome sequencing. A total of 785 DETs were obtained from the HF and control groups. These DETs were mainly enriched in the immune responses, especially Th1, Th2, and Th17 cell differentiation processes. Furthermore, flow cytometry results revealed that the proportion of Th1 and Th17 cells increased in patients with HF compared to controls, while the proportion of Th2 cells decreased. Differentially expressed genes in the HF and control groups associated with Th1, Th2, and Th17 cell differentiation were quantified using qRT-PCR. We also identified variable splicing events of sarcomere genes (e.g., <i>MYBPC3, TNNT2, TTN, FLNC</i>, and <i>TTNI3</i>). In addition, we detected 4,892 transcription factors and 406 lncRNAs associated with HF. Our analysis based on full-length transcript sequencing provided an analysis perspective in a dog model of HF, which is valuable for molecular research in an increasingly relevant large animal model of HF.
BibTeX
@inproceedings{liang2021full,
  author = {Xiaoyan Liang and Zechen Bai and Feifei Wang and Yafan Han and Huaxin Sun and Jiasuoer Xiaokereti and Ling Zhang and Xianhui Zhou and Yanmei Lu and Baopeng Tang},
  title = {{Full-Length Transcriptome Sequencing: An Insight Into the Dog Model of Heart Failure}},
  booktitle = {Frontiers in Cardiovascular Medicine},
  year = {2021},
  doi = {10.3389/fcvm.2021.712797},
}
Figure